COMMUNIQUÉS West-GlobeNewswire

Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
15/12/2025
CONSHOHOCKEN, Pa., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the J.P. Morgan Annual Healthcare Conference on Monday, January 12 [...]
IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications
15/12/2025
Findings provide scientific insights into the contributions of IDO1 and PD-L1 vaccination to PD-1 blockade for the treatment of metastatic melanoma Five-year analysis of median progression free survival was 25.5 months [...]
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results
15/12/2025
Conference call and webcast to be held at 8 a.m. ET on December 16, 2025 BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel [...]
Kyverna Therapeutics Announces Proposed Public Offering of Common Stock
15/12/2025
EMERYVILLE, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX) (“Kyverna”), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune [...]
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
15/12/2025
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development [...]
AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers
15/12/2025
PRESS RELEASE AB SCIENCE ANNOUNCES A NEW PUBLICATION ON BIORXIV THAT IDENTIFIES AND CHARACTERIZES A NOVEL SMALL SYNTHETIC MOLECULE, AB8939, AS A PROMISING DRUG CANDIDATE FOR TREATING REFRACTORY ACUTE MYELOID LEUKEMIA ( [...]
AB Science annonce une nouvelle publication sur biorxiv identifiant AB8939 comme un candidat médicament prometteur pour le traitement de la leucémie myéloïde aiguë réfractaire et potentiellement d'autres cancers
15/12/2025
COMMUNIQUÉ DE PRESSE AB SCIENCE ANNONCE UNE NOUVELLE PUBLICATION SUR BIORXIV QUI IDENTIFIE ET CARACTÉRISE UNE NOUVELLE MOLÉCULE SYNTHÉTIQUE, AB8939, COMME UN CANDIDAT MÉDICAMENT PROMETTEUR POUR LE TRAITEMENT DE LA [...]
Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline
15/12/2025
PARIS, FRANCE, 15 December 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced it has completed the acquisition of ImCheck Therapeutics, a private French biotechnology company pioneering next-generation immuno- [...]
Ipsen finalise l'acquisition d'ImCheck Therapeutics, élargissant ainsi son portefeuille de produits oncologiques
15/12/2025
PARIS, FRANCE, 15 DECEMBRE 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) annonce aujourd’hui avoir finalisé l'acquisition d'ImCheck Therapeutics, une société privée française de biotechnologie pionnière dans le domaine des [...]
Booking Health Releases 2026 Rankings of Germany’s Most Trusted Cancer Hospitals for International Patients
15/12/2025
Langenfeld, Germany, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Booking Health , a leading platform for international medical travel, announced today the release of its 2026 rankings of Germany’s most trusted cancer hospitals. [...]
Face-Art Maestro Dr Jaffer Khan Pioneers Aesthetic Artistry for Advanced Plastic Surgery in Dubai
15/12/2025
The Visionary Surgeon Who Uses Face Art Techniques to Sculpt Faces, Ensuring Timeless Harmony and Profound Confidence DUBAI, United Arab Emirates, Dec. 15, 2025 (GLOBE NEWSWIRE) -- In Dubai, Dr. Jaffer Khan is [...]
Oncotelic Therapeutics and Brush and Key Foundation Announce Publication in International Journal of Molecular Sciences Highlighting Context-Dependent Biomarkers in Liver and Pancreatic Cancer
15/12/2025
AGOURA HILLS, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) in collaboration with the Brush and Key Foundation , today announced the publication of a peer-reviewed research article [...]
Trinity Biotech Expands Global Rollout of High-Capacity Column System for FDA-Cleared HbA1c Testing Solution After Securing Regulatory Clearances
15/12/2025
Company advances its mission to deliver next-generation diabetes management solutions and expand global market penetration Next-generation column technology enhances efficiency, expands recurring revenue potential, and [...]
BetaGlue Therapeutics Receives Belgium Ministry of Health Approval for YntraDose Clinical Trial in Unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC)
15/12/2025
MILAN, Dec. 15, 2025 (GLOBE NEWSWIRE) -- BetaGlue ® Therapeutics (“BetaGlue” or the “Company”), a pioneering Italian clinical-stage oncology company developing an innovative radiotherapy solution for the targeted [...]
BetaGlue Therapeutics obtient l’autorisation du ministère de la Santé belge pour mener un essai clinique portant sur YntraDose dans le traitement du cancer du pancréas localement avancé non résécable (uLA-PDAC)
15/12/2025
MILAN, 15 déc. 2025 (GLOBE NEWSWIRE) -- BetaGlue ® Therapeutics (« BetaGlue » ou la « Société »), une société italienne pionnière en oncologie au stade clinique, développant une solution innovante de radiothérapie pour [...]
SPR Reaches Milestone 50,000th Implant of the SPR® SPRINT® PNS System
15/12/2025
CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- SPR announced that it has reached 50,000 implants of the SPRINT ® PNS System, a significant milestone recognizing the impact of treatment for patients with 60-day peripheral [...]
Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma
15/12/2025
Promising data show a median overall survival of 18.6 months, with 40% of patients alive at 2 years. Results suggest that nuclear GSK-3β expression may help identify patients most likely to respond to treatment of a [...]
Noom Enters Longevity Health Space with Proactive Health Microdose GLP-1Rx Program Designed to Help Millions Address the Biomarkers Most Linked to Future Disease
15/12/2025
New program pairs microdoses of GLP-1 medication with Noom’s powerful behavior-change program and at-home biomarker testing to track the health impact of combining GLP-1 therapy with healthy habits. PRINCETON, N.J., Dec [...]
ORYZON Announces the Voting Results of December 2025 Extraordinary General Shareholders' Meeting
15/12/2025
37.8% of voting rights present or represented All resolutions were approved MADRID and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage [...]

Pages